The reduced tumor suppression activity of hypomorphic variants of the TP53 gene was used by Indeglia and colleagues to corroborate PADI4 as a p53 target. The study makes a noteworthy advancement in comprehending the downstream implications of TP53–PDI4, including potential predictions of survival and the efficacy of immunotherapy.

See related article by Indeglia et al., p. 1696 (4).

You do not currently have access to this content.